A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started ...

One way to cope with cuts in HIV prevention funding is to continue to push to increase the number of people who self-test for HIV instead of getting tested at a clinic or hospital, experts at a series ...

The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the ...

JOHANNESBURG (AP) — Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV ...

This new FDA-approved shot is designed to break down the barriers that have kept too many people from accessing PrEP.

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

HIV jab has signed a deal to supply the costly injection at a knock-down price to as many as two million people in poorer countries.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they liveThe Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) ...

The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...